BCL2 and acute myeloid leukemia: It has been shown to have potent activity against primary AML cells when used in combination with Bcl-2 inhibitors, including cells with adverse cytogenetic abnormalities and categorized for poor-risk outcomes.118 The combination therapy has also been successful in reducing viability of leukemia progenitor cells and LSCs in in vitro and in vivo models, further demonstrating its clinical potential.118